In vitro and in vivo cytogenetic effects of recombinant interleukin-2 on human lymphocytes. 1994

T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
Division of Medical Oncology, National Cancer Center Research Institute, Tokyo, Japan.

To determine the cytogenetic effects of rIL-2, we investigated the rIL-2-induced sister chromatid exchange (SCE) and chromosomal aberrations in human peripheral lymphocytes in vitro and in patients given rIL-2 as a 24-hour infusion for 28 consecutive days. No significant increase in SCE frequency and chromosomal aberrations was observed after in vitro incubation of lymphocytes with 100 U/ml of rIL-2. A daily rIL-2 dose of 6.6 x 10(5) U/m2 did not induce any significant effect on SCE frequency and chromosomal aberrations while a marked increase was observed in the percentage of IL-2 receptor positive cells and HLA-DR positive cells. Although IL-2 therapy is only in developmental stage, our results suggest there is little or no potential mutagenic and/or carcinogenic hazard with this agent.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
January 1984, Cancer treatment reports,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
January 1986, Mutation research,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
February 1986, Journal of biological response modifiers,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
December 1980, Koku Eisei Gakkai zasshi,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
April 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
October 1970, Deutsche medizinische Wochenschrift (1946),
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
September 1986, Veterinary immunology and immunopathology,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
January 1980, IARC scientific publications,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
January 1990, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
T Shinkai, and T Tamura, and T Sano, and A Kojima, and K Eguchi, and Y Sasaki, and Y Ohe, and N Saijo
January 1985, Lymphokine research,
Copied contents to your clipboard!